Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
SYSTEMIC SUPPORT Unlike localized treatments, oral BPC-157 can provide systemic benefits, supporting overall integrity as it circulates through the body
This latter hypothesis has yet to be tested
The most significant published evidence to date comes from a phase 2 randomised controlled trial (Jastreboff et al., New England Journal of Medicine , 2023), which demonstrated substantial dose-dependent weight loss in adults with obesity over 24 weeks, with continued weight reduction observed at 48 weeks
We launched generic Liraglutide for diabetes and obesity in the Netherlands as our first direct-to-market GLP-1 in the EU
